{"id":77251,"date":"2026-02-09T12:04:10","date_gmt":"2026-02-09T12:04:10","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/dsm-firmenich-provides-preliminary-comparative-figures-following-the-announced-divestment-of-animal-nutrition-health-anh\/"},"modified":"2026-02-09T12:04:10","modified_gmt":"2026-02-09T12:04:10","slug":"dsm-firmenich-provides-preliminary-comparative-figures-following-the-announced-divestment-of-animal-nutrition-health-anh","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/dsm-firmenich-provides-preliminary-comparative-figures-following-the-announced-divestment-of-animal-nutrition-health-anh\/","title":{"rendered":"dsm-firmenich provides preliminary comparative figures following the announced divestment of Animal Nutrition & Health (ANH)"},"content":{"rendered":"
\n

Press Release<\/b><\/p>\n

dsm-firmenich provides preliminary comparative figures following the announced divestment of Animal Nutrition & Health (ANH) <\/b><\/p>\n

Kaiseraugst (Switzerland), Maastricht (Netherlands), February 9, 2026<\/p>\n

Following the announced divestment of Animal Nutrition & Health (ANH) activities to CVC Capital Partners, the assets and liabilities of the divested business have been classified as Assets Held for Sale, and the financial results of the ANH activities have been reclassified to Discontinued Operations.<\/p>\n

The financial results are restated to present the Continuing Operations of dsm-firmenich, ensuring a comparable view of the company\u2019s ongoing performance over time. The Group will report its full-year 2025 results on February 12, 2026, in line with this new classification.<\/p>\n

In Annex 1, comparative figures are provided for the most recent four reported quarters
(Q4 2024, Q1 2025, Q2 2025, Q3 2025) as well as full-year 2024, for the following line items:
Net Sales, Adjusted EBITDA, Adjusted EBITDA margin, and Organic Sales Growth. <\/p>\n

New reporting structure<\/b>
The following summary outlines the primary structural adjustments that are reflected in the restated numbers for 2024 and 2025:<\/p>\n

Perfumery & Beauty<\/b> (P&B) is restated primarily for Aroma Ingredients and Pentapharm. These activities are included in Discontinued Operations.<\/p>\n

Taste, Texture & Health<\/b> (TTH) is restated primarily for Yeast Extracts, and certain vitamin sales included in the ANH divestment (\u201cnon-differentiated vitamins\u201d), which moved to Discontinued Operations, and to include Bovaer (the methane-reducing feed ingredient) which moved from ANH to TTH.<\/p>\n

Health, Nutrition & Care<\/b> (HNC) is restated primarily for Marine Lipids, and certain vitamin sales included in the ANH divestment (\u201cnon-differentiated vitamins\u201d), which moved to Discontinued Operations. Veramaris (the 50\/50 joint-venture for algae-based Omega-3) is transferred from ANH to HNC.<\/p>\n

Therefore, the Discontinued Operations include ANH (incl. the feed enzymes activities divested in June 2025), Aroma Ingredients, Marine Lipids, Yeast Extracts, and certain vitamin sales included in the ANH divestment (\u201cstraights or non-differentiated vitamins\u201d) and other small divestments, following dsm-firmenich\u2019s portfolio review as communicated at the Capital Markets Day in 2024.<\/p>\n

KPI adjustment <\/b>
dsm-firmenich will provide an updated \u2018Core EBIT\u2019 figure, adding back merger-related amortisation as well as the amortisation of other intangible assets recognized through purchase-price allocations (PPA) from all pre-merger acquisitions, to allow for easier comparison with industry peers.<\/p>\n

Further comparative details to be provided<\/b>
Comparative figures for the 2024 income statement that are restated accordingly, will be provided at full year 2025 reporting on February 12, 2026.<\/p>\n

Further reporting adjustments to be made in 2026<\/b>
The Nutrition Improvement activities which are primarily a sustainability-driven program focusing on nutritional support and food aid programs, will transfer from Health, Nutrition & Care to Group Sustainability and will be reported under Corporate Activities as from Q1 2026. These activities generate approximately \u20ac20 million in quarterly net sales and operate around break-even at the Adjusted EBITDA level. The restatement in annex does not yet include this reporting change.<\/p>\n

The annex is shared in the attachments.\u00a0<\/strong><\/p>\n

<\/p>\n

About dsm-firmenich<\/b>
As innovators in nutrition, health, and beauty, dsm-firmenich reinvents, manufactures, and combines vital nutrients, flavors, and fragrances for the world\u2019s growing population to thrive. With our comprehensive range of solutions, with natural and renewable ingredients and renowned science and technology capabilities, we work to create what is essential for life, desirable for consumers, and more sustainable for people and the planet. dsm-firmenich is a Swiss company, listed on the Euronext Amsterdam, with operations in almost 60 countries and revenues of more than \u20ac12 billion. With a diverse, worldwide team of nearly 30,000 employees, we bring progress to life every day, everywhere, for billions of people.
www.dsm-firmenich.com<\/u><\/a>\u00a0<\/p>\n

For more information<\/b><\/p>\n

Media relations<\/b>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Investor relations<\/b>
Robin Roothans \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Dave Huizing
tel. +41 (0)79\u00a0280 03 96\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0tel. +31 (0)88\u00a0425 7306
e-mail media@dsm-firmenich.com<\/a> \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0e-mail investors@dsm-firmenich.com<\/a><\/p>\n

Forward-looking statements<\/u>
This press release may contain forward-looking statements with respect to dsm-firmenich\u2019s future (financial) performance and position. Such statements are based on current expectations, estimates and projections of dsm-firmenich and information currently available to the company. dsm-firmenich cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. dsm-firmenich has no obligation to update the statements contained in this press release, unless required by law. This communication contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. The English language version of the press release is leading.<\/p>\n

\n Attachments<\/strong>\n<\/p>\n